Friday, February 10, 2017 4:06:39 PM
SRPT:
Not to debate the merits of efficacy or price (which have had numerous discussions here in the past) but the merits of the stock as an investment I found today to be a good (re)entry. Here is some of my high level thinking:
1-I don't see Exondys 51 being removed from the market any time soon (at least 4-5 years if ever). Patients/families want to use the drug so that is not an issue as well.
2-Insurance has been a hurdle but they are getting some coverage and it seems more are and more are starting with time/publicity/patient effort.
3-The average weight (and thus cost per patient) is going to be much higher then SRPT guided so revenue should grow at a faster rate as reimbursement becomes less and less of an issue.
4-There is still the EU possibility of approval and x-US market to add a substantial number of patients.
5-I really like what Ed Kaye has done to keep focusing on the market not just the initial effort. I like that he licensed 2 GT's, a couple collaborations and most importantly the next generation PPMO which has the potential to provide substantial efficacy.
With those being said as a previous long (I didn't get hurt too bad just on paper as I bought very low but sold well off the high) is there a support group I can join
?
Not to debate the merits of efficacy or price (which have had numerous discussions here in the past) but the merits of the stock as an investment I found today to be a good (re)entry. Here is some of my high level thinking:
1-I don't see Exondys 51 being removed from the market any time soon (at least 4-5 years if ever). Patients/families want to use the drug so that is not an issue as well.
2-Insurance has been a hurdle but they are getting some coverage and it seems more are and more are starting with time/publicity/patient effort.
3-The average weight (and thus cost per patient) is going to be much higher then SRPT guided so revenue should grow at a faster rate as reimbursement becomes less and less of an issue.
4-There is still the EU possibility of approval and x-US market to add a substantial number of patients.
5-I really like what Ed Kaye has done to keep focusing on the market not just the initial effort. I like that he licensed 2 GT's, a couple collaborations and most importantly the next generation PPMO which has the potential to provide substantial efficacy.
With those being said as a previous long (I didn't get hurt too bad just on paper as I bought very low but sold well off the high) is there a support group I can join
?
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
